Table 2.
Characteristics of the studies that combined physical activity with polyphenols.
| References, Country | Length months | Age range (mean/SD) | % of females | N (PA/ PA-PP) | BMI by groups (mean/SD) | Health status | PA Suppl | PA-PP Suppl form: polyphenol type and dosage per day | Physical activity protocol |
|---|---|---|---|---|---|---|---|---|---|
| Barsalani et al. (26) Canada | 6 | 50-70 | 100 | 39 (21/18) | PA: 29.75 (27.9-31.5)* PA-PP: 30.29 (28.1-32.4)* |
Healthy | Cellulose Capsule | Capsule: Isoflavone 70 mg (Daidzein 62.9%) |
3 x 60 min/week AE+ RE, M-Int |
| Llaneza et al. (27) Spain | 24 | 50-64 (56.7/3.5) |
100 | 65 (32/33) | PA: 30.6/4.7 PA-PP: 30.5/4.2 |
Healthy | No Suppl | Glycine max: Isoflavone 80 mg (Genistein 76%) |
5 x 30 min/week AE or walk |
| Choquete et al. (28) Canada | 6 | 50-70 (58.7/5.3) |
100 | 34 (18/16) | PA: 29.1/3.9 PA-PP: 30.2/3.5 |
Healthy | No Suppl | Capsule: Isoflavone 70 mg (Daidzein 62.9%) |
3 x 60 min/week AE. RE, M-Int |
| Llaneza et al. (37) Spain | 6 | 50-64 (58.0) |
100 | 70 (37/33) | PA: 35.2/4.78 PA- PP: 34.7/4.67 |
Healthy | No Suppl | Glycine max: Isoflavone 80 mg (Genistein 76%) |
420 min/week Walk daily |
| Llaneza et al. (38) Spain | 24 | 50-64 (56.2) |
100 | 90 (44/46) | PA: 30.7/4.67 PA- PP: 29.6/4.23 |
IR | No Suppl | Capsule: Isoflavone 40 mg |
420 min/week Walk daily |
| Orsatti et al. (39) Brazil | 9 | 45-70 (56.2) |
100 | 33 (18/15) | PA: 26.0/3.0 PA- PP: 30.3/4.7 |
Healthy | Lactose Capsule | Glycine max: Isoflavone 100 mg (Genistein 50%) |
2 x 60 min/week RE, M-Int |
| Aubertin-Leheudre et al. (40) Canada | 12 | 50-70 (58.0/5.0) |
100 | 39 (18/21) | PA:30.0/2.0 PA- PP: 30.0/5.0 |
Healthy | Placebo Capsule | Capsule: Isoflavone 70 mg (Daidzein 62.9%) |
3 x 60 min/week AE, M-Int |
| Hill et al. (41) Australia | 3 | 45-70 | 100 | 38 (19/19) | PA: 31.39/0.73+
PA- PP: 30.65/0.59+ |
Healthy | Lactose Capsule | TEAVIGO: EGCG 300 mg | 3 x 60 min/week Running, Int |
| Gahreman et al. (42) Australia | 3 | (26.0/0.7)+ | 0 | 43 | PA:28.67/0.78+
PA- PP: 29.04/1.28+ |
Healthy | Placebo Capsule | GT Capsule: Catechins 562.5 mg (60 mg CF) |
3 x 30 min/week AE, V-Int |
| Maki et al. (43) US | 3 | 21-65 (48.0) | 47.7 | 107 (51/56) | PA: 32.2/ 0.5+
PA-PP: 32.5/ 0.5+ |
Healthy | Placebo Beverage | GT: Catechins 625 mg (39 mg CF) |
3 x 60 min/week M-Int |
| Faghihzadeh et al. (36) Iran | 3 | (45.2) | 30 | 48 (24/24) | PA: 28.75/3.5 PA- PP: 28.35/3.49 |
NAFLD | Placebo Capsule | Capsule: Resveratrol 500 mg |
3 x 3 0min/week M-Int |
AE, aerobic exercise; BMI, body mass index (kg/m2); CF, caffeine; EGCG, epigallocatechin-gallate; GT, green tea; Int, Intensive; IR, insulin resistance; N, number of participants in both groups and (by groups); NAFLD, non-alcoholic fatty liver disease; M-Int, moderate-intensive; PA, physical activity intervention group; PA-PP, physical activity plus polyphenols intervention group; RE, resistance exercise; SD, standard deviation; Suppl, supplementation; US, United States; V-Int, very-intensive.
*
95% Confidence Interval.
+
Mean values with their standard error of the mean.